Caracterización de los resultados correspondientes al brote de sarampión de Madrid de 2019 en las muestras clínicas procesadas en el Laboratorio Regional de Salud Pública.

  1. Sanz Moreno, Juan Carlos 1
  2. Vadillo, Isabel
  3. Gómez, Teresa 2
  4. Echevarría, Juan Emilio 3
  5. Fernández, Aurora 3
  6. de Ory, Fernando
  1. 1 Unidad de Microbiología Clínica. Laboratorio Regional de Salud Pública de la Comunidad. Dirección General de Salud Pública. Consejería de Sanidad. Comunidad de Madrid. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP).
  2. 2 Unidad de Microbiología Clínica. Laboratorio Regional de Salud Pública de la Comunidad. Dirección General de Salud Pública. Consejería de Sanidad. Comunidad de Madrid.
  3. 3 Laboratorio Nacional de Referencia de Sarampión y Rubéola. Centro Nacional de Microbiología (CNM). Instituto de Salud Carlos III (ISCIII). Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP).
Show affiliations +
Journal:
Revista Madrileña de Salud Pública: REMASP

ISSN: 2659-9716

Year of publication: 2019

Volume: 1

Issue: 7

Pages: 1-6

Type: Article

DOI: 10.36300/REMASP.2019.013 DIALNET GOOGLE SCHOLAR

More publications in: Revista Madrileña de Salud Pública: REMASP

Abstract

In the spring of 2019 an increase of cases of measles have been detected in Madrid. The aims of this study is to describe the type of studied clinical samples and the results obtained in this outbreak. Between April 1 and June 25 of 2019 one hundred ninety three biological samples corresponding to 109 clinical suspicions of measles were processed. The serological determinations (IgM and IgG against measles and rubella) were carried out by ELISA. The ARN amplification of measles and rubella virus were performed by RT-PCR.   Forty four cases of measles were confirmed. Two cases have been vaccinated recently and both presented the vaccine genotype A. All wild strains amplified (21) were D8. In Thirty two confirmed cases both samples of pharyngeal exudate and blood were available for RT-PCR for serology respectively. In all 32 the RT-PCR resulted positive (sensitivity 100%, CI95% 86.7- 99.7) while in 22 the IgM was positive (sensitivity 68.8%, CI95% 49.9- 83.3). Inversely, in 49 discarded measles suspicions samples of pharyngeal exudate and blood were available and in all 49 the RT-PCR was negative (specificity 100%, CI95% 90.9- 99.8). In one sample corresponding to a discarded measles suspicion the IgM was positive (specificity 98.0%, CI95% 87.8- 99.9). In the measles and rubella elimination era the standards of surveillance must go directed to detect all possible cases. For this motive is precise the correct timely obtaining of adequate biological samples (sera and especially pharyngeal exudate).

Bibliographic References

  • - Robert A, Funk S, Kucharski AJ. The measles crisis in Europe-the need for a joined-up approach. Lancet. 2019; 393(10185): 2033. https://doi.org/10.1016/S0140-6736(19)31039-6
  • - Plans-Rubió P. Low percentages of measles vaccination coverage with two doses of vaccine and low herd immunity levels explain measles incidence and persistence of measles in the European Union in 2017-2018. Eur J Clin Microbiol Infect Dis. 2019; 38(9): 1719-1729. https://doi.org/10.1007/s10096-019-03604-0
  • - García Comas L, Ordobás Gavín M, Sanz Moreno JC, Ramos Blázquez B, Rodríguez Baena E, Córdoba Deorador E, et al. Community-wide measles outbreak in the Region of Madrid, Spain, 10 years after the implementation of the Elimination Plan, 2011-2012. Hum Vaccin Immunother. 2017; 13(5): 1078-1083. https://doi.org/10.1080/21645515.2016.1267081
  • - Comunidad de Madrid. Plan de Eliminación del Sarampión en la Comunidad de Madrid. Documento Técnico de Salud Pública nº 73. [Consultado 17 de septiembre de 2019]. Disponible en: http://www.madrid.org/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobkey=id&blobtable=MungoBlobs&blobwhere=1158610320129&ssbinary=true
  • - Comunidad de Madrid. Plan de Eliminación del Sarampión, Rubéola y Síndrome de Rubéola Congénita en la Comunidad de Madrid. Madrid. Consejería de Sanidad. Dirección General de Atención Primaria. Documentos Técnicos de Salud Pública nº D134, 2013. [Consultado 17 de septiembre de 2019]. Disponible en: http://www.madrid.org/bvirtual/BVCM017438.pdf
  • - Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Protocolos de la Red Nacional de Vigilancia Epidemiológica. Madrid: Red Nacional de Vigilancia Epidemiológica, 2013. [Consultado 17 de septiembre de 2019]. Disponible en: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/PROTOCOLOS/PROTOCOLOS%20EN%20BLOQUE/PROTOCOLOS_RENAVE-ciber.pdf
  • - Ramsay M, Brugha R, Brown D. Surveillance of measles in England and Wales: implications of a national saliva testing programme. Bull World Health Organ. 1997; 75(6): 515-521.
  • - Hübschen JM, Bork SM, Brown KE, Mankertz A, Santibanez S, Ben Mamou M, et al. Challenges of measles and rubella laboratory diagnostic in the era of elimination. Clin Microbiol Infect. 2017; 23(8): 511-515. https://doi.org/10.1016/j.cmi.2017.04.009
  • - Chua KYL, Thapa K, Yapa CM, Somerville LK, Chen SC, Dwyer DE, et al. What assay is optimal for the diagnosis of measles virus infection? An evaluation of the performance of a measles virus real-time reverse transcriptase PCR using the Cepheid SmartCycler(®) and antigen detection by immunofluorescence. J Clin Virol. 2015; 70: 46-52. https://doi.org/10.1016/j.jcv.2015.07.004
  • -WHO. Measles Vaccine-Preventable Diseases Surveillance Standards Last updated: October 15, 2018. [Consultado 17 de septiembre de 2019]. Disponible en: https://www.who.int/immunization/monitoring_surveillance/burden/vpd/WHO_SurveillanceVaccinePreventable_11_Measles_R2.pdf?ua=1
  • - Risco-Risco C, Masa-Calles J, López-Perea N, Echevarría JE, Rodríguez-Caravaca G. Epidemiology of measles in vaccinated people, Spain 2003-2014. Enferm Infecc Microbiol Clin. 2017; 35(9): 569-573. https://doi.org/10.1016/j.eimc.2016.05.001
  • -Patel MK, Gibson R, Cohen A, Dumolard L, Gacic-Dobo M. Global landscape of measles and rubella surveillance. Vaccine. 2018; 36(48): 7385-7392. https://doi.org/10.1016/j.vaccine.2018.10.007
Data source: Dialnet